美国加州大学旧金山分校Mark S. Anderson等研究人员展望了1型糖尿病治疗的新前沿。该综述论文于2019年12月12日在线发表于国际一流学术期刊《细胞—代谢》。
研究人员表示，1型糖尿病是由免疫介导的胰岛β细胞破坏引起的一种自身免疫疾病，导致终生绝对胰岛素缺乏。
近一个世纪以来，胰岛素替代疗法一直是大多数患有这种疾病的人的唯一疗法。技术上的最新进展以及我们对β细胞发育、葡萄糖代谢以及该疾病潜在的免疫发病机制的了解已促进了新的治疗和预防方法。
免疫疗法的发展已经改变，转为靶向具有耐受性的胰岛特异性免疫途径，从而推动了疗法的发展。
这些疗法可预防或逆转该疾病，同时避免了过去疗法中的广泛免疫抑制毒性。
附：英文原文
Title: New Frontiers in the Treatment of Type 1 Diabetes
Author: Jeremy T. Warshauer, Jeffrey A. Bluestone, Mark S. Anderson
Issue&Volume: December 12, 2019
Abstract: ype 1 diabetes is an autoimmune disease caused by the immune-mediated destruction of pancreatic β cells that results in lifelong absolute insulin deficiency. For nearly a century, insulin replacement has been the only therapy for most people living with this disease. Recent advances in technology and our understanding of β cell development, glucose metabolism, and the underlying immune pathogenesis of the disease have led to innovative therapeutic and preventative approaches. A paradigm shift in immunotherapy development toward the targeting of islet-specific immune pathways involved in tolerance has driven the development of therapies that may allow for the prevention or reversal of this disease while avoiding toxicities associated with historical approaches that were broadly immunosuppressive. In this review, we discuss successes, failures, and emerging pharmacological therapies for type 1 diabetes that are changing how we approach this disease, from improving glycemic control to developing the “holy grail” of disease prevention.
DOI: 10.1016/j.cmet.2019.11.017
Source: https://www.cell.com/cell-metabolism/fulltext/S1550-4131(19)30624-2
Cell Metabolism：《细胞—代谢》，创刊于2005年。隶属于细胞出版社，最新IF：31.373
官方网址：https://www.cell.com/cell-metabolism/home
投稿链接：https://www.editorialmanager.com/cell-metabolism/default.aspx
本期文章：《细胞—代谢》：Online/在线发表
